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Introduction:  Osteoradionecrosis  (ORN)  is a severe,  generally  irreversible  complication  of  radiotherapy
due  to  failure  of  healing.  The pentoxifylline-tocopherol  combination  decreases  the  superﬁcial  ﬁbrosis
induced  by radiotherapy.  Potentiation  by  Clodronate  (PENTOCLO)  appears  to  be  effective  in  ORN  of  the
mandible.  The  objectives  of  this  study  were  to  evaluate  the  efﬁcacy  and safety  of  PENTOCLO  to  treat
osteoradionecrosis  of the  mandible.
Methods:  Retrospective  study  of 27  patients  with  a mean  age  of  65  ± 12 years,  managed  for  ORN  of the
mandible  secondary  to irradiation  for head  and  neck  cancer,  treated  by the  PENTOCLO  protocol  between
January  2010  and  March  2011.  The  primary  endpoint  was  regression  of exposed  bone  until complete
healing.  Assessment  was  both  clinical  (measurement  of  mucosal  ulceration)  and  radiological  (panoramic
dental  x-rays)  before  treatment,  after  antibiotic-corticosteroid  combination  therapy  for one month  (M1),
and then  after  3, 6, 12  months  of  PENTOCLO.
Results:  An improvement  of mucosal  ulceration  was  observed  in 16/21  patients  after  3 months  and
in  12/17  patients  after  6 months  of  PENTOCLO.  Healing  was  obtained  in 16  patients.  Median  healing
time  was  82  days  (range:  32–266),  and  was  shorter  after  surgery  and  radiotherapy  (49 days)  and  longer
after  chemoradiotherapy  (169 days).  Radiological  healing  was achieved  later  than  clinical  healing  with
improvement  in  9 out  of  20 patients  at 3 months.  The  safety  and  efﬁcacy  of  treatment  were  evaluated  by
intraoral  clinical  examination,  and  assessment  of  feeding,  weight  and  analgesic  consumption.  No  patient
discontinued  treatment  because  of adverse  effects.
Conclusion: The  PENTOCLO  protocol  achieved  clinical  and radiological  regression  of  ORN with,  in parallel,
a reduction  of the  indications  for major  surgery.  These  preliminary  results  need  to  be conﬁrmed  by
prospective  studies  comprising  quality  of life  assessment.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Osteoradionecrosis (ORN) of the mandible is a severe, generally
rreversible complication of radiotherapy due to failure of healing.
RN of the mandible occurs several weeks to several years after
adiotherapy for head and neck cancer, generally within 3 years [1].
RN is usually associated with an intraoral mucosal defect and frag-
le mandibular bone. The clinical presentation varies from patient
o patient, but most patients experience intense local pain due to
ntraoral mucosal break [2].
∗ Corresponding author.
E-mail addresses: robard-l@chu-caen.fr, robard laetitia@hotmail.com
L. Robard).
http://dx.doi.org/10.1016/j.anorl.2013.11.006
879-7296/© 2014 Elsevier Masson SAS. All rights reserved.ORN is an uncommon disease with a highly variable incidence
over time and according to various studies (0.4 to 56%) [3], but the
current incidence appears to be less than 5% [4]. The mean age of
onset is 50 years [5], with a sex-ratio of 1.6 males for 1 female
[6]. ORN usually occurs between 4 months and 3 years after radio-
therapy, but it has been reported to occur at any time during the
patient’s life following head and neck radiotherapy [7].
Many factors predispose to the development of the ORN:
tumour size and its position in relation to the bone [8], treat-
ment(s) of the tumour (surgery, radiotherapy and chemotherapy),
the patient’s age and comorbidities. The incidence and sever-
ity of ORN increase with poor dental status, dental extraction
sites, local trauma and excessive alcohol and tobacco consump-
tion [5,6,9]. The incidence of ORN increases with the total dose
of radiotherapy (> 66 Gy) [5]. Brachytherapy or surgical resection
of mandibular tumour [8] also increases the incidence of ORN.
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Table 1
Study population.
Characteristics n
Number of patients treated n = 27
Age on inclusion: mean ± standard deviation (range) 65 ± 12
(46–87)
Tumour (n)
Oral cavity 13
Oropharynx 11
Other 3
TNM (n)
T1 2
T2  6
T3  6
T4  11
TX  2
N0  8
N1  6
N2  13
M0  27
Treatment (n)
Radiotherapy alone 1
Concomitant chemoradiotherapy 7
Surgery + radiotherapy alone 15
Surgery + sensitized radiotherapy 4
Mean interval between end of RT-diagnosis of ORN (months) 39 ± 36
(2–122)
Interval between diagnosis of ORN-inclusion in PENTOCLO
protocol
0  to 3 months (n) 13
>  3 months (n) 13
Mean interval for patients with an interval > 3 months
(months)
22.93 ± 18.3
(3–57)
Treatment of ORN prior to PENTOCLO (n)
Medical 10
Surgery 4
HBO 0
Initial clinical status (n)
No exposed bone or ulceration 2
Minimal mucosal ulceration 2
Exposed bone < 2 cm 11
Exposed bone 2 to 4 cm 2
Exposed bone > 4 cm or fracture 0
Initial radiological status (n)
No bone lysis 3
Cortical bone lysis 9
Major bone lysis 1034 L. Robard et al. / European Annals of Otorhinolary
ntensity-Modulated Radiation Therapy (IMRT) appears to reduce
he incidence of osteoradionecrosis of the mandible [10,11], as new
adiotherapy techniques tend to decrease the incidence of ORN as
 result of more precise adaptation of the target volume and by
ndividual or even conformal dosimetry.
Many articles have been published on this subject since the
rst clinical description of osteoradionecrosis in 1922 [12], but the
athophysiology has been only partially elucidated. In 1983, Marx
roposed the hypothesis that ORN is due to the triad of hypocel-
ularity, hypoxia and hypovascularity [13]. In 1993, Dambrain
mphasized the role of ischemia and infection [14]. Hypovascu-
arity could account for the predominance of ORN involving the
ngle and body of the mandible, which are supplied exclusively
y the inferior alveolar artery, resulting in a more fragile blood
upply in the premolar, molar and retromolar sectors [7]. In 2002,
elanian and Lefaix proposed a histopathological deﬁnition of ORN,
hich consists of devitalization of bony trabeculae by destruction
f osteocytes and loss of osteoblasts, processes that differ from
hat observed in osteomyelitis (necrotic acute inﬂammation of the
one marrow and compact bone) [15]. ORN is the end-result of
rogressive pathological processes of bone matrix and cell destruc-
ion poorly compensated by defective osteogenesis in favour of
adiation-induced ﬁbrotic scar tissue [15].
Various deﬁnitions have been proposed for ORN, but it can
e generally considered to correspond to progressive radiation-
nduced ischaemic necrosis of the bone associated with soft tissue
ecrosis spreading a variable distance from the tumour, a recur-
ence or metastatic disease [16]. As bone tissue absorbs up to 6
imes more ionising radiation than the adjacent soft tissues, it
s therefore more susceptible [15]. Several authors have tried to
eﬁne a clinical and radiological classiﬁcation of ORN. The 3-stage
lassiﬁcation proposed by Marx and Myers appears to be the most
elevant [17]:
stage 1: less than 2 mm of exposed bone with or without pain and
with radiological signs of diffuse demineralisation;
stage 2: more than 2 mm of exposed bone;
stage 3: pathological fracture, oral ﬁstula, ﬁstula or lesion of the
inferior border of the mandible.
Management of ORN has not been standardized and is essen-
ially based on symptomatic treatments comprising mouthwashes
nd repeated courses of antibiotics. Various treatment options
ave been proposed to manage refractory ORN: drug treatments
vasodilators), hyperbaric oxygen therapy, and sometimes major
urgery, with variable results [18].
PENTOCLO therapy is based on the concept of antioxidant and
ntiﬁbrotic treatment of ﬁbro-atrophy [19]. In the setting of ORN,
ENTOCLO is preceded by an initial 4 to 6 weeks of combination
nti-inﬂammatory, antifungal and antibiotic treatment to control
ocal superinfection in the irradiated zone (intraoral exposed bone)
esponsible for acute episodes of inﬂammation, especially actino-
ycosis. The PENTOCLO combination is then initiated to reduce
he already constituted ﬁbrotic process (pentoxifylline-vitamin E
ombination), reduce bone destruction (clodronate) and stimulate
ealing in combination necrotic zone. Pentoxifylline increases the
evel of oxygenation in the tissues and vitamin E has an antioxi-
ant action. The pentoxifylline-vitamin E combination signiﬁcantly
ecreases radiation-induced ﬁbrosis via a synergistic action [20].
he addition of clodronate inhibits osteoclastic bone destruction
21] (Fig. 1).Delanian et al. reported that the pentoxifylline-tocopherol com-
ination was not only able to reduce radiation-induced ﬁbrosis [20],
ut also promoted rapid healing of minimal forms of ORN [9]. Sub-
equent potentiation with clodronate (PENTOCLO) improved theseFracture 4
ORN: osteoradionecrosis; HBO: hyperbaric oxygen therapy.
results in refractory mandibular ORN in a phase II single-centre trial
recently published by Delanian et al. [18].
The objectives of the present study were to study the efﬁ-
cacy and safety of PENTOCLO therapy for osteoradionecrosis of the
mandible in our institution.
2. Patients and methods
2.1. Population
Between January 2010 and March 2011, 27 patients were treated
with the PENTOCLO combination for a osteoradionecrosis of the
mandible at centre Franc¸ ois-Baclesse (CRLCC) and in the head and
neck surgery department at the University Hospital of Caen.
This series comprised 22 men  and 5 women, with 22 smokers
(81%), 8 of whom continued smoking at the time of initiation of
treatment. Nineteen patients continued regular alcohol consump-
tion at the time of discovery of their tumour (70%). The mean age
on inclusion was  65 (± 12) years (Table 1).
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Thirteen patients were managed for a tumour of the oral cavity,
1 for a tumour of the oropharynx, 2 patients for lymphadenopathy
ith an unknown primary and one patient for a parotid tumour.
he histology was squamous cell carcinoma in all cases except
or the parotid tumour (undifferentiated). No active tumour (local
ecurrence or metastasis) was present at the time of initiation of
ENTOCLO.
.2. Previous radiotherapy
Radiotherapy had been used alone or in combination with
hemotherapy and/or surgery. The total dose delivered was 54 to
36 Gy (during two courses of radiotherapy in the same patient)
ith a median dose of 68 Gy. All patients were treated by photons
hen electron conformal radiotherapy. No patient was treated by
rachytherapy. Only 7 patients developed ORN after a radiothe-
apy dose of 58 Gy, while 20 cases of ORN occurred after a dose of
8 Gy or more.
.3. Osteoradionecrosis of the mandible
ORN predominantly affected the body (12 patients) or the angle
f the mandible (7 patients) or both (3 patients). The mean length of
xposed bone (largest dimension of the lesion) was 1.3 cm (range:
.1–3 cm). Prior to treatment with PENTOCLO, ORN had been man-
ged by antibiotics in 10 patients, for a mean duration of 21 days,
ostly consisting of amoxicillin-clavulanic acid or erythromycin.
our patients had been treated surgically (mandibular resection
ith or without reconstruction). Hyperbaric oxygen therapy had
ot been performed in any of the patients of this series.
The mean interval between the end of radiotherapy and the
iagnosis of ORN was 39 ± 36 months (range: 2–122 months). The
ean RT-ORN interval was 19 months for the 7 patients treated
y concomitant chemoradiotherapy, 51 months for the 15 patients
reated by adjuvant radiotherapy alone and 23 months for the 4
atients treated by adjuvant sensitized radiotherapy. The patient
reated by exclusive radiotherapy presented an RT-ORN interval of
6 months.
ORN secondary to radiotherapy for cancer of the oral cavity was
ore severe than ORN observed in patients treated for a tumour of
he oropharynx, as 4/13 patients had at least 2 cm of exposed boneaccording to Delanian and Lefaix [17]).
after treatment of a tumour of the oral cavity versus only 1 patient
after treatment of a tumour of the oropharynx.
2.4. PENTOCLO protocol
The ﬁrst treatment phase, lasting 4 to 6 weeks, was  designed
to reduce tissue inﬁltration and consisted of daily treatment
with a combination of 2 g of amoxicillin-clavulanic acid, 1 g of
ciproﬂoxacin, 50 mg  of ﬂuconazole, 20 mg of prednisone and 20 mg
of omeprazole.
The second phase of PENTOCLO treatment was continued until
complete healing with a daily dose of 800 mg of pentoxifylline, 1 g
of tocopherol, 1600 mg  of clodronate 5 days a week from Monday
to Friday and 20 mg  of prednisone 2 days a week, on Saturday and
Sunday. This treatment was  administered according to the protocol
described by Delanian et al.
2.5. Follow-up
Assessment was  performed at a deﬁned time-point, regardless
of the duration of treatment. This report presents the preliminary
results. The number of patients treated therefore decreased with
increasing follow-up.
Patients attended an initial assessment with the same doctor at
M0 and then at one month (M1), three months (M3), six months
(M6) and twelve months (M12). Clinical assessment comprising
intraoral examination and a global assessment (feeding, weight,
pain and analgesic consumption) were performed at each visit.
Radiological assessment was  performed by the same practitioner,
based on panoramic dental x-rays and CT scan in 3 cases.
2.6. Statistical analysis
The primary endpoint of the study was the course of intra-
oral exposed bone related to ORN. This clinical assessment was
rated according to stages before (M0) and during treatment (M1,
M3,  M6,  M12) with stage 0 = no exposed bone or ulceration; stage
1 = minimal mucosal ulceration; stage 2 = exposed bone < 2 cm;
stage 3 = exposed bone measuring 2 to 4 cm;  stage 4 = exposed
bone > 4 cm or fracture.
Initial radiological criteria were classiﬁed in three stages:
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Table 2
Clinical and radiological course, progressive follow-up.
Clinical course
1 month Between
1 and 3
months
Between
3  and 6
months
Between
3  and 6
months
Improvement 14 12 8 4
Deterioration 1 1 2 0
Stability 10 8 7 3
Total 25 21 17 7
Radiological course
1 month Between
1 and 3
months
Between
3  and 6
months
Between
3  and 6
months
Improvement 6 6 1 436 L. Robard et al. / European Annals of Otorhinolary
R0 = no bone lysis;
R1 = cortical bone lysis;
R2 = major bone lysis; R3 = fracture.
These criteria were determined subjectively in order to facilitate
eproducible interpretation of radiological examinations.
Quantitative variables were expressed as the mean, median
nd standard deviation and qualitative variables were expressed
n terms of improvement, deterioration, stability.
. Results
.1. Safety
All patients presented good adherence (100%) to treatment.
afety was acceptable: 16/27 patients were able to receive the
omplete treatment, while treatment had to be adjusted in 6
atients: 4 for minimal toxicity requiring dose reduction (nau-
ea with clodronate for 3 patients). Two patients immediately
tarted treatment at the second phase as they presented no signs
f infection. Two patients had to discontinue treatment for another
edical cause related to comorbidities (death in one case and mal-
utrition in one case). No patient discontinued treatment because
f adverse effects.
.2. Associated sequestrectomies
Twelve (45%) of the 27 patients required one or more outpa-
ient sequestrectomies during treatment, with an average of 2.8 per
atient, while no sequestrectomies were performed in 15 patients.
.3. Local clinical assessment
Only the initial assessment was available for two  patients:
ne patient died 2 months after initiation of treatment (unknown
ause), and the other patient developed an intercurrent problem
ith malnutrition requiring placement of a gastrostomy tube and
iscontinuation of treatment.
Among the 25 patients evaluated at the time of initiation of the
econd phase of treatment, 14 (56%) obtained clinical improve-
ent, only 1 patient deteriorated and the other 10 patients
emained stable. The mean duration of the ﬁrst treatment phase
as 1.4 months (6 weeks).
Twenty-one patients received the PENTOCLO protocol between
he two ﬁrst assessments (M1-M3): 12 of the 21 cases of ORN
ere improved, only 1 patient deteriorated and the other 8 patients
emained stable (Table 2).
Seventeen patients were treated between the two  assessments
3-M6: 8 cases of ORN were improved, while 2 patients dete-
iorated. At this stage of treatment, between M0  and M6, 12/17
atients had improved (70%) (Fig. 2).
Seven patients were treated between assessments M6-M12,
nd 4 cases of ORN were improved. All patients obtained clini-
al improvement compared to the initial assessment at M0:  the
ocal status was satisfactory for these 7 patients with ORN only
easuring less than 2 cm of exposed bone.
The mean healing time after initiation of treatment was  110 ± 76
ays (range: 37–266): 167 days for patients initially treated by
oncomitant chemoradiotherapy, 49 days for patients treated by
djuvant radiotherapy alone and 101 days for patients treated by
djuvant sensitized radiotherapy. Clinical healing was deﬁned by
he absence of mucosal ulceration or exposed bone on examination
f the oral cavity.
Overall, 16 (59%) of the 27 patients were clinically healed after
n average of 110 days (3.6 months). On subgroup analysis of theDeterioration 2 2 2 1
Stability 14 12 11 1
Total 22 20 14 6
8 patients who  continued to smoke at the time of initiation of PEN-
TOCLO therapy, only 3 (37%) obtained mucosal healing versus 11
(58%) in the smoking cessation group. Similarly, the mean healing
time for patients not drinking alcohol was  49 days versus 101 days
for those who continued to drink.
All of the 6 patients with minimal ORN (stage 0–1) at the initial
assessment were healed. Eight of the 14 patients initially presenting
exposed bone < 2 cm (stage 2) were healed and only 1 of the 5
patients with more advanced ORN (stage 3–4) was healed.
3.4. Radiological assessment
An initial radiological assessment was  performed in 26 of the 27
patients, as one patient died before treatment. Nineteen patients
(70%) presented signs of cortical or major bone lysis at this initial
assessment.
Panoramic dental x-rays were not performed in 3 patients at
the M1  assessment. More than 50% of the 22 cases of ORN evalu-
ated remained stable and 6 were improved. Six out of 20 patients
improved between assessments M1  and M3  and 12/20 patients
remained stable (Table 2). Six out of 14 patients improved between
assessments M0  and M6  and only one patient improved between
assessments M3  and M6.
At M6,  among the 12 patients with clinical improvement, 5 pre-
sented radiological improvement and 2 presented deterioration of
the radiological signs. In contrast, at M12, after 12 months of PEN-
TOCLO, 5/7 patients (71%) presented improvement of radiological
signs (Fig. 3).
3.5. General clinical assessment
At the initial M0  assessment, mean weight on inclusion was  3 kg
(range: 45–85): 65.3 kg for men and 49.3 kg for women. The median
weight recorded at each visit was 62 kg.
At the initial assessment, 23 (85%) of the 27 patients had exclu-
sively oral feeding regardless of the stage of ORN, and 3/27 had
strictly enteral nutrition (11%). After six months of treatment, 14/17
patients had exclusively oral feeding (82%) and only 1 patient
required enteral nutrition (6%). At the fourth assessment, no patient
still required enteral nutrition and 5 out of 7 patients ate exclusively
by mouth.
At the time of initiation of PENTOCLO, 11 patients presented
limited mouth opening limitation; this trismus was improved dur-
ing treatment in 3 patients.
Initially, one half of patients [13] required analgesics. No change
was observed at three months, but, at six months, 9 (53%) of the
L. Robard et al. / European Annals of Otorhinolaryngology, Head and Neck diseases 131 (2014) 333–338 337
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Fig. 2. Clinical course for 
7 patients no longer required any analgesics. After twelve months
f treatment, 4 (57%) out of 7 patients no longer required any anal-
esics.
. Discussion
.1. Study population
The mean age of onset of ORN in this series was 64 years, older
han the mean age reported in the literature [5]. The usual male
redominance was observed (4.4 men  for 1 woman). Patients with
umours of the oral cavity and oropharynx were at greater risk
f developing osteoradionecrosis of the mandible (7.8) and rep-
esented 89% of patients in this series. Osteoradionecrosis was
bserved after a mean interval of 39 months, i.e. slightly more than
 years, in line with the data of the literature [1]. Cases of ORN
ccurring more than 10 years after radiotherapy were observed in
his series. Twenty of the 27 patients had received a total irradiation
ose greater than 66 Gy, which is known to be a risk factor for ORN
5]. Osteoradionecrosis was observed more rapidly after concomi-
ant chemoradiotherapy than after surgery followed by adjuvant
adiotherapy. Concomitant chemotherapy appeared to inﬂuence
he time to onset of ORN. ORN predominantly involved the body
nd angle of the mandible (22 out of 27 patients), which can be
xplained by the blood supply derived exclusively from the inferior
lveolar artery [7].
Ongoing smoking at the time of initiation of treatment con-
tituted a risk factor for poor healing of ORN. Smoking was  a
onfounding factor for assessment of healing in this study. Man-
gement of ORN consists not only of treatment of eroded bone, but
lso management of risk factors including alcohol and smoking. The
nﬂuence of continued alcohol consumption was not evaluated in
his study.
Various treatments have been proposed for the manage-
ent of osteoradionecrosis of the mandible. Conservative medical
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Fig. 3. Clinical and radiolots followed for 6 months.
treatment generally consists of antibiotics and optimized oral
hygiene [16], but, when used alone, fails to achieve resolution of
ORN in the majority of cases. Marx reported a one-year healing
rate of 8% in response to conservative medical treatment in a series
of 112 patients [22]. Based on the theory of hypovascularity and
hypoxia, hyperbaric oxygen therapy (HBO) has been proposed since
1973 to treat mandibular ORN. However, a prospective random-
ized double-blind study by Annane et al. showed that HBO did not
provide any beneﬁt in the treatment of mandibular ORN with 33%
of healing in the placebo group versus 19% in the group treated
with HBO [23]. Surgery may  be indicated to remove necrotic tissue
in order to achieve satisfactory local control of ORN [24], espe-
cially for the treatment of ORN refractory to medical treatment
[25]. Various techniques can be used, especially local ﬂaps (such
as a nasolabial local ﬂap). In the presence of a fracture or threat-
ened fracture, surgery inevitably involves mandibular resection
with reconstruction by free bone ﬂap whenever possible. However,
these complicated and expensive techniques [26] are only indicated
in highly selected patients (good general and vascular status) and
must be performed by experienced teams (double surgical team,
long operations).
Medical treatment by PENTOCLO has already been demon-
strated to be effective for minimal ORN [9] and refractory ORN
[21]. The phase II single-centre trial published in 2011 by Delanian
et al. showed that PENTOCLO therapy is well tolerated (few adverse
effects), allowing mucosal and bone healing of refractory ORN  [18],
as complete mucosal healing was obtained in every case after a
median follow-up of 9 months. Clodronate belongs to the class of
biphosphonates that are known to generate the osteochemonecro-
sis. However, clodronate possesses speciﬁc properties, as it is the
only non-angiogenic biphosphonate and the only member of this
class with osteoblast stimulation properties. Its inhibitory effects
on osteoclasts are also 1000 times lower and the concentrations
used in the treatment of ORN are lower than those used in other
indications [27].
th 3 months 6 months 12 months
Radiolo gica l ass essm ent
Deterior aon
Stability
Improvement
gical course of ORN.
3 ngolo
m
w
l
L
b
t
a
(
t
h
t
r
a
2
t
n
t
p
t
t
e
p
s
t
s
c
o
e
S
o
p
H
w
v
t
a
a
c
s
w
m
b
p
5
h
a
C
a
a
t
o
a
e
o
h
r
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[38 L. Robard et al. / European Annals of Otorhinolary
Clinical improvement was obtained in 70% of cases after 6
onths of PENTOCLO in this study. Healing with mucosal recovery
as obtained in 60% of cases after a mean interval of 110 days, i.e.
ess than 4 months, while continuing outpatient sequestrectomies.
onger healing times were observed for patients initially treated
y concomitant chemoradiotherapy (167 days, i.e. 118 days longer
han for patients treated by surgery and adjuvant radiotherapy
lone). This well-tolerated and relatively inexpensive treatment
D200 per month, i.e. D1200 for 6 months) appears to be an attrac-
ive alternative for the treatment of all stages of ORN. However,
ealing time increases with increasing severity of ORN. At cen-
re Franc¸ ois-Baclesse, the number of cases of major free bone ﬂap
econstruction surgery in these indications has decreased: an aver-
ge of 4 free bone ﬂaps per year were performed between 2004 and
009, while only two cases have required surgery for fractures at
he ORN site since the introduction of PENTOCLO therapy.
These preliminary results conﬁrm the results published by Dela-
ian et al. [18]. The lower local control rate could be largely related
o continuation of smoking in our series. However, this study
resents a number of limitations due to the small sample size and
he bias related to missing data and the preliminary data collec-
ion, as well as the reader-dependent assessment of radiological
xaminations.
Orthopantomography, a simple and inexpensive examination,
rovides essential data for the radiological follow-up of ORN: the
tate of bone demineralisation, periosteal thickening, Paget-like
rabecular structure, and complications (bone sequestra, fracture,
igns of osteomyelitis) [14]. However, radiological signs are delayed
ompared to clinical signs: they are not observed immediately but
nly after 3 to 6 months, as radiological signs only become appar-
nt after a signiﬁcant degree of demineralisation (30 to 50%) [4].
igns of healing on dental panoramic x-rays were also delayed in
ur study. Radiological signs were improved in only 5 of the 12
atients with clinical improvement after 6 months of PENTOCLO.
owever, after 12 months of treatment, 5 of the 7 patients who
ere improved clinically were also improved radiologically.
PENTOCLO therapy was well tolerated and was associated with
ery good adherence (100%). Treatment changes were minimal and
reatment never had to be discontinued because of adverse effects,
s in the phase II trial reported by Delanian [18]. PENTOCLO therapy
lso allowed a reduction of analgesic consumption, although pain
an also be related to other factors. Patients did not lose weight and
ome patients were able to resume oral feeding. Mouth opening
as also improved for several patients.
Other treatment modalities are currently under develop-
ent for the management of mandibular ORN such as hybrid
one substitutes (MBCP granules and total bone marrow trans-
lantation).
. Conclusion
ORN is a severe complication of radiotherapy related to failure of
ealing for which no standard treatment is available. ORN is gener-
lly observed when irradiation doses to the mandible exceed 66 Gy.
ancers of the oral cavity and oropharynx treated by radiotherapy
re at greatest risk of ORN, which usually involves the body or the
ngle of the mandible. Medical treatment by PENTOCLO appears
o be an effective, inexpensive treatment that is almost devoid
f adverse effects. It therefore constitutes a good alternative to
vailable treatments for the management of mandibular ORN. Nev-
rtheless, preventive treatment remains essential, based on good
ral hygiene, preventive dentistry prior to radiotherapy and alco-
ol and smoking cessation. New radiotherapy techniques may  also
educe the incidence of ORN. The results of this study need to
[
[gy, Head and Neck diseases 131 (2014) 333–338
be conﬁrmed by prospective randomized placebo-controlled trials.
The present study could be completed by a quality of life assess-
ment in order to optimize the global management of these patients.
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